Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Updated data on roxadustat in patients with lower-risk MDS from the open-label portion of an ongoing randomized, double-blind phase III study suggest that roxadustat reduces transfusion burden and enables transfusion independence.
Format: Microsoft PowerPoint (.ppt)
File Size: 414 KB
Released: December 14, 2020


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable summary slideset from a live webinar on treatment approaches for lower-risk, higher-risk, and relapsed/refractory MDS, from Clinical Care Options (CCO)

Michael J. Savona, MD
Program Director
Jacqueline S. Garcia, MD Amer Zeidan, MBBS
Released: December 23, 2021

Results from the phase III PANTHER trial evaluating pevonedistat + azacitidine vs azacitidine in higher-risk MDS/CMML or low-blast AML from ASH 2021, as reported by Clinical Care Options (CCO)

Released: December 20, 2021

Pelabresib (CPI-0610) monotherapy active in patients with myelofibrosis in the ongoing phase II MANIFEST trial presented at ASH 2021 and reported by Clinical Care Options (CCO)

Released: December 16, 2021

Rusfertide substantially reduced need for phlebotomy and improved hematocrit control in patients with phlebotomy-dependent polycythemia vera in a study presented at ASH 2021 and reported by Clinical Care Options (CCO)

Released: December 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings